Market Cap
AU$150.3b
Last Updated
2020/02/17 10:32 UTC
Data Sources
Company Financials +
Executive Summary
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally.
Rewards
Risk Analysis
Snowflake Analysis
Outstanding track record with excellent balance sheet.
Similar Companies
Share Price & News
How has CSL's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CSL has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
3.0%
CSL
2.9%
AU Biotechs
1.5%
AU Market
1 Year Return
77.8%
CSL
78.8%
AU Biotechs
15.6%
AU Market
Return vs Industry: CSL underperformed the Australian Biotechs industry which returned 80.1% over the past year.
Return vs Market: CSL exceeded the Australian Market which returned 16.1% over the past year.
Shareholder returns
| CSL | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.0% | 2.9% | 1.5% |
| 30 Day | 10.8% | 10.4% | 0.4% |
| 90 Day | 21.2% | 20.9% | 4.1% |
| 1 Year | 80.0%77.8% | 80.9%78.8% | 20.6%15.6% |
| 3 Year | 188.3%177.6% | 183.7%173.5% | 37.1%18.7% |
| 5 Year | 296.3%268.4% | 271.2%246.9% | 50.9%17.1% |
Price Volatility Vs. Market
How volatile is CSL's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
The CSL (ASX:CSL) Share Price Is Up 269% And Shareholders Are Boasting About It3 weeks ago | Simply Wall St
What Kind Of Shareholders Own CSL Limited (ASX:CSL)?1 month ago | Simply Wall St
Why CSL Limited (ASX:CSL) Looks Like A Quality CompanyValuation
Is CSL undervalued compared to its fair value and its price relative to the market?
50.5x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CSL (A$332.55) is trading above our estimate of fair value (A$260.85)
Significantly Below Fair Value: CSL is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CSL is poor value based on its PE Ratio (50.5x) compared to the Biotechs industry average (36.8x).
PE vs Market: CSL is poor value based on its PE Ratio (50.5x) compared to the Australian market (18.8x).
Price to Earnings Growth Ratio
PEG Ratio: CSL is poor value based on its PEG Ratio (3.4x)
Price to Book Ratio
PB vs Industry: CSL is overvalued based on its PB Ratio (16.7x) compared to the AU Biotechs industry average (2.8x).
Next Steps
Future Growth
How is CSL forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
15.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CSL's forecast earnings growth (15% per year) is above the savings rate (1.1%).
Earnings vs Market: CSL's earnings (15% per year) are forecast to grow faster than the Australian market (9.6% per year).
High Growth Earnings: CSL's earnings are forecast to grow, but not significantly.
Revenue vs Market: CSL's revenue (10.4% per year) is forecast to grow faster than the Australian market (4.2% per year).
High Growth Revenue: CSL's revenue (10.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CSL's Return on Equity is forecast to be high in 3 years time (32.4%)
Next Steps
Past Performance
How has CSL performed over the past 5 years?
9.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CSL has high quality earnings.
Growing Profit Margin: CSL's current net profit margins (22.4%) are higher than last year (21.8%).
Past Earnings Growth Analysis
Earnings Trend: CSL's earnings have grown by 9.4% per year over the past 5 years.
Accelerating Growth: CSL's earnings growth over the past year (11.2%) exceeds its 5-year average (9.4% per year).
Earnings vs Industry: CSL earnings growth over the past year (11.2%) exceeded the Biotechs industry 7.3%.
Return on Equity
High ROE: CSL's Return on Equity (33%) is considered high.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is CSL's financial position?
Financial Position Analysis
Short Term Liabilities: CSL's short term assets ($5.9B) exceed its short term liabilities ($2.7B).
Long Term Liabilities: CSL's short term assets ($5.9B) exceed its long term liabilities ($5.3B).
Debt to Equity History and Analysis
Debt Level: CSL's debt to equity ratio (75.4%) is considered high.
Reducing Debt: CSL's debt to equity ratio has reduced from 76.9% to 75.4% over the past 5 years.
Debt Coverage: CSL's debt is well covered by operating cash flow (51.4%).
Interest Coverage: CSL's interest payments on its debt are well covered by EBIT (20x coverage).
Balance Sheet
Inventory Level: CSL has a high level of physical assets or inventory.
Debt Coverage by Assets: CSL's debt is covered by short term assets (assets are 1.3x debt).
Next Steps
Dividend
What is CSL's current dividend yield, its reliability and sustainability?
0.83%
Current Dividend Yield
Upcoming Dividend Payment
Purchase CSL before the 'Buy Limit' to receive their next dividend payment.
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: CSL's dividend (0.83%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.29%).
High Dividend: CSL's dividend (0.83%) is low compared to the top 25% of dividend payers in the Australian market (5.5%).
Stability and Growth of Payments
Stable Dividend: CSL is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.
Growing Dividend: CSL is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: CSL is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CSL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.4yrs
Average management tenure
CEO
Paul Perreault (62yo)
6.6yrs
Tenure
US$11,718,242
Compensation
Mr. Paul R. Perreault, BA (Psychology) has been the Chief Executive Officer and Managing Director of CSL Limited since July 1, 2013. Mr. Perreault serves as the Chief Executive Officer and Managing Directo ...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD11.72M) is above average for companies of similar size in the Australian market ($USD3.72M).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Executive Director | 6.6yrs | US$11.72m | 0.028% $42.2m | |
| Chief Financial Officer | 4.1yrs | US$3.09m | 0.0032% $4.8m | |
| Chief Scientific Officer | 1.3yrs | US$2.79m | 0.020% $29.5m | |
| Executive VP of Legal & Group General Counsel | 0yrs | US$2.50m | 0.0016% $2.4m | |
| Executive VP & Chief Human Resources Officer | 2.2yrs | US$1.45m | 0.00013% $195.4k | |
| Executive VP & Chief Commercial Officer | 2.4yrs | US$2.55m | 0.00017% $255.5k | |
| Executive VP and Head of Research & Development | 1.3yrs | US$2.41m | 0.00012% $180.4k | |
| Chief Operating Officer | 0.7yrs | no data | no data | |
| Head of Investor Relations | 0yrs | no data | no data | |
| Head of Public Affairs | 0yrs | no data | no data |
2.4yrs
Average Tenure
59yo
Average Age
Experienced Management: CSL's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Executive Director | 6.6yrs | US$11.72m | 0.028% $42.2m | |
| Chief Scientific Officer | 1.3yrs | US$2.79m | 0.020% $29.5m | |
| Non Executive Director | 4yrs | US$229.71k | 0.00065% $977.1k | |
| Independent Non-Executive Director | 0.2yrs | no data | no data | |
| Independent Chairman | 1.3yrs | US$444.35k | 0.039% $59.1m | |
| Independent Non-Executive Director | 8.5yrs | US$215.92k | 0.0011% $1.7m | |
| Independent Non-Executive Director | 9yrs | US$222.52k | 0.00078% $1.2m | |
| Independent Non-Executive Director | 2yrs | US$200.99k | 0.000010% $15.0k | |
| Independent Non-Executive Director | 6.5yrs | US$202.98k | 0.00062% $932.0k |
4.0yrs
Average Tenure
62yo
Average Age
Experienced Board: CSL's board of directors are considered experienced (4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
CSL Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: CSL Limited
- Ticker: CSL
- Exchange: ASX
- Founded: 1916
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$150.321b
- Shares outstanding: 453.88m
- Website: https://www.csl.com
Number of Employees
Location
- CSL Limited
- 45 Poplar Road
- Parkville
- Victoria
- 3052
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CSL | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Jun 1994 |
| CSJ | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jun 1994 |
| CMXH.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jun 1994 |
| CSL | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Jun 1994 |
| CSL N | BMV (Bolsa Mexicana de Valores) | Yes | Ordinary Shares | MX | MXN | Jun 1994 |
| CSLL.Y | OTCPK (Pink Sheets LLC) | SPON ADR EACH REPR 0.5 ORD | US | USD | Oct 2008 | |
| CSJA | DB (Deutsche Boerse AG) | SPON ADR EACH REPR 0.5 ORD | DE | EUR | Oct 2008 |
Biography
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/17 10:32 |
| End of Day Share Price | 2020/02/17 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.